Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Sep;43(9):2109-15.
doi: 10.1128/AAC.43.9.2109.

Activity of pleconaril against enteroviruses

D C Pevear  1 , T M Tull, M E Seipel, J M Groarke
Affiliations

Activity of pleconaril against enteroviruses

D C Pevear et al. Antimicrob Agents Chemother. 1999 Sep.

Abstract

The activity of pleconaril in cell culture against prototypic enterovirus strains and 215 clinical isolates of the most commonly isolated enterovirus serotypes was examined. The latter viruses were isolated by the Centers for Disease Control and Prevention during the 1970s and 1980s from clinically ill subjects. Pleconaril at a concentration of </=0.03 microM inhibited the replication of 50% of all clinical isolates tested. Ninety percent of the isolates were inhibited at a drug concentration of </=0.18 microM. The most sensitive serotype, echovirus serotype 11, was also the most prevalent enterovirus in the United States from 1970 to 1983. Pleconaril was further tested for oral activity in three animal models of lethal enterovirus infection: coxsackievirus serotype A9 infection in suckling mice, coxsackievirus serotype A21 strain Kenny infection in weanling mice, and coxsackievirus serotype B3 strain M infection in adult mice. Treatment with pleconaril increased the survival rate in all three models for both prophylactic and therapeutic dosing regimens. Moreover, pleconaril dramatically reduced virus levels in target tissues of coxsackievirus serotype B3 strain M-infected animals. Pleconaril represents a promising new drug candidate for potential use in the treatment of human enteroviral infections.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Structure of pleconaril.
FIG. 2
FIG. 2
Activity of pleconaril in mouse models of enterovirus infection. (A) CVA9 in suckling mice; (B) CVA21 strain Kenny in weanling mice; (C) CVB3 strain M in adult mice.
FIG. 3
FIG. 3
CVB3 strain M titers in pancreases (A) and hearts (B) of placebo- or pleconaril-treated adult mice.
FIG. 4
FIG. 4
Serum pleconaril levels in adult mice after single oral dosing.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abdel-Rahman S M, Kearns G L. Single oral dose escalation pharmacokinetics of pleconaril (VP 63843) capsules in adults. J Clin Pharmacol. 1999;39:613–618. - PubMed
    1. Abzug M J, Levin M J, Rotbart H A. Profile of enterovirus disease in the first two weeks of life. Pediatr Infect Dis J. 1993;12:820–824. - PubMed
    1. Abzug M J. Perinatal enterovirus infections. In: Rotbart H A, editor. Human enterovirus infections. Washington, D.C: ASM Press; 1995. pp. 221–238.
    1. Badger J, Minor I, Kremer M J, Oliveira M A, Smith T J, Griffith J P, Guerin D M A, Krishnaswamy S, Luo M, Rossmann M G, McKinlay M A, Diana G D, Dutko F J, Fancher M, Rueckert R R, Heinz B A. Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc Natl Acad Sci USA. 1988;85:3304–3308. - PMC - PubMed
    1. Bailey T R, Diana G D, Kowalczyk P F, Akullian V, Eissenstat M A, Cutliffe D, Mallamo J P, Carabateas P M, Pevear D C. Antirhinoviral activity of heterocyclic analogs of Win 54954. J Med Chem. 1992;35:4628–4633. - PubMed

MeSH terms

LinkOut - more resources